Getting high level care to low and middle income countries

How will ASCO combat cancer disparities?

Chemotherapy-free strategies in treating leukaemia

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

Multiple myeloma science from EHA 2019

CAR T-cell therapy for treating acute leukaemia

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone